Trial Profile
A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability and Recommended Phase II Dose (RP2D) of GLG-801 in patients with Advanced Solid Tumors (Phase I); and safety, tolerability and anticancer activity of GLG-801 in patients with Metastatic TNBC (Phase II)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 28 Jan 2019
Price :
$35
*
At a glance
- Drugs GLG 801 (Primary)
- Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Renal cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors GLG Pharma
- 12 Oct 2018 New trial record